Stock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth

Stock Track

Oct 30, 2024

Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.

While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.

Sage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179660506"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179660506\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179660506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179660506","market":"us","top_or_hot":-1,"title":"Stock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth","media":"Stock Track","content":"<p>Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.</p>\n\n<p>While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.</p>\n\n<p>Sage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-30 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.</p>\n\n<p>While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.</p>\n\n<p>Sage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAGE","symbol_name":"Sage Therapeutics","start_time":0,"source_url":"","article_id":"1179660506","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179660506","pubTimestamp":1730295327,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Sage Therapeutics Inc.  plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression  market, generating $22.1 million in total revenue for the quarter , the company's overall financial performance and updates on other programs failed to impress investors.Sage reported a net loss of $93","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAGE":"Sage Therapeutics"},"translate_title":"尽管Zurzuvae增长，但第三季度盈利令人失望，Sage Therapeutics股价暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1},"content_text":"Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.\nWhile Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.\nSage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}